Articles Archives - Page 138 of 747

WednesdayFeb 21, 2024 1:30 pm

DealFlow Events Presents the Venture Debt Conference March 6 in NYC

The Venture Debt Conference is set for March 6, 2024, at the Edison Ballroom in Manhattan Now in its second year, this is the largest forum dedicated to non-dilutive financing strategies for emerging growth companies The conference also explores various forms of financing available to start-ups, including term loans, revenue-based financing, receivables financing and equipment financing, among others Venture debt has rapidly grabbed attention as an attractive complement to venture capital funding for fast-growing start-ups. A catch-all term for loans designed to meet the unique needs of venture-backed start-ups in the innovation economy, venture debt has gained increasing popularity as…

WednesdayFeb 21, 2024 12:45 pm

Astiva Health Navigating the Future of Healthcare with a Vision for Culturally Responsive Medicare Advantage

Astiva Health's culturally inclusive approach sets a new precedent in the Medicare Advantage market Enrollment in Medicare Advantage programs is projected to encompass half of all Medicare enrollments by 2024, with Astiva Health leading the charge in service expansion and inclusivity Astiva Health is committed to reshaping healthcare delivery with increased access to quality healthcare for diverse populations In a landscape where more individuals are becoming eligible for Medicare, Astiva Health is carving out a niche as a rapidly growing Medicare Advantage Prescription Drug (“MAPD”) health plan. Astiva stands out by redefining personalized and comprehensive healthcare standards. Reflecting its success,…

WednesdayFeb 21, 2024 12:00 pm

Sigyn Therapeutics Inc. (SIGYD) Advancing Novel Therapeutic Technologies to Enhance the Benefit of Cancer Therapies, Treat Pathogen-Associated Conditions Beyond the Reach of Drugs

Sigyn Therapeutics has designed a pipeline of medical technologies to improve cancer treatment outcomes by reducing the circulating presence of bloodstream particles that decoy or block the intended delivery of cancer therapies. At present, less than 2% of therapeutic antibodies and chemotherapy doses administered to cancer patients are delivered to tumor cell targets The company has also created a medical technology to reduce the circulating presence of off-target chemotherapy from the bloodstream to reduce patient toxicity and organ damage The company’s lead therapeutic candidate addresses life-threatening conditions that are pathogen-induced and not addressed with drug therapies Sigyn Therapeutics (OTCQB: SIGYD,…

WednesdayFeb 21, 2024 11:15 am

SenesTech Inc. (NASDAQ: SNES) Promotes its Non-lethal Rodent Birth Control Products in Lytham Investor Forum

Arizona-based SenesTech Inc., is dramatically improving pest management technicians’ toolbox with its patent-pending Evolve(R) soft bait birth control product for rodents SenesTech’s Evolve(R) product joins the liquid ContraPest(TM) product in providing a non-lethal solutions to reducing rodent populations The company’s CEO and CFO recently appeared virtually at the Lytham Partners 2024 Investor Select Conference, participating in a fireside chat interview and meeting one-on-one with potential investors SenesTech also recently announced increased distribution of its product in partnership with Poppe Enterprises LLC, — a company that serves the grain management market in Nebraska, South Dakota, North Dakota, Kansas, Wyoming, Iowa, and…

WednesdayFeb 21, 2024 10:30 am

SuperCom Ltd. (NASDAQ: SPCB) Expands its Project Portfolio with New Canada Project; Reinforces its Position as a Leader in the Electronic Monitoring Industry

SuperCom, a global provider of digital identity and electronic monitoring (“EM”) solutions, just announced a new project in the tracking sector with a renowned Canadian industry partner The initial phase of the project is set to launch in the first quarter of the 2024 calendar year, with significant potential for expansion in both scale and scope The project will include the transition from RF-based tracking technology to new GPS tech using SuperCom’s PureOne devices SuperCom (NASDAQ: SPCB), a global leading provider of digital identity and electronic monitoring solutions and services to governments and institutions, just announced a new project with…

WednesdayFeb 21, 2024 9:45 am

GEMXX Corp. (GEMZ) to Capitalize on Growing Trend in India’s Jewelry and Colored Gemstone Markets

GEMXX recently announced insights into the burgeoning jewelry and colored gemstones markets in India The jewelry market in India is expected to grow by US$21.54 billion between 2023 and 2027, while the colored gemstones market is projected to reach $1.9 billion by 2033 from an estimated $707.8 million in 2024 GEMXX, a leading producer of top-quality finished Ammolite, anticipates that this rare gemstone has the potential to attract a significant portion of buyers in India seeking something innovative or distinct from conventional colored gemstones The company is positioned to capitalize on the growing trend in the colored gemstones market, with…

WednesdayFeb 21, 2024 9:00 am

Diamond Lake Minerals Inc. (DLMI) Sees Fractional STO Ownership as a Solution to Real Estate Market Volatility and Insecurity

Utah-based Diamond Lake Minerals is developing its vision of an umbrella parent company that not only holds a variety of industry-crossing subsidiaries, but that also serves as a gateway for cautious investors looking to dip a toe into digital assets The company’s vertically integrated portfolio will include holdings that are infused with security token offerings registered with the U.S. Securities and Exchange Commission Diamond Lake views its digital asset-in-a-real world asset gateway as a hedge against market volatility, especially for real estate properties that may be over-leveraged and struggling to stay afloat while seeking favorable lending terms A recent spate…

TuesdayFeb 20, 2024 12:00 pm

DealFlow Events Presents the Activist Investor Conference March 21 in NYC

The Activist Investor Conference will take place on March 21, 2024, at 237 Park Avenue, one of Manhattan’s premiere meeting venues The 14th annual edition of the conference features investors, corporate board members and governance experts, advisory firms, proxy solicitors and finance professionals who will delve into the latest trends within shareholder activism This year’s conference features a number of keynote presentations by experts in the field, including Patrice Bonfiglio, Sean Donohue, and Jon Feldman Shareholder activism emerged in the 1970s and 1980s as a tool to drive the process of price formation, improve corporate governance and defend minority shareholder…

TuesdayFeb 20, 2024 11:15 am

SOBRsafe Inc. (NASDAQ: SOBR) Releases Case Studies Demonstrating SOBRcheck(TM)’s Performance; CEO Provides Comprehensive Update

SOBRsafe recently published three case studies that empirically demonstrate the performance of its alcohol screening technology, SOBRcheck(TM), based on customer data, experiences, and results SOBRcheck can be used as a safe, convenient, and fast replacement for cumbersome and unhygienic breathalyzers One case study shows that SOBRcheck enabled TerraTech to achieve a 100% pass rate per week against an estimated industry average weekly violator rate of between 60% and 70% By deploying SOBRcheck, Big Horn County has been able to provide cost-effective alcohol monitoring services for more than 100 community members, while Alternatives Inc. has achieved 4x faster throughput at check-in/check-out…

TuesdayFeb 20, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D

Lexaria, a global innovator in drug delivery platforms to enhance bioavailability, announced recently that it will focus on GLP-1 applications for diabetes and weight loss for the 2024 calendar year Chris Bunka, Lexaria’s CEO, has expressed his confidence in the company’s direction, reiterating the intention to demonstrate the superior performance of GLP-1 drugs processed with its patented DehydraTECH(TM) technology The company looks to build on the success of the early-stage results achieved in 2023, and looks to embark on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a…

Site Search

Company Search

Category: Articles